Drug delivery refers to the technology utilized to present the drug to the desired body site for drug release and absorption. Intranasal drug delivery offers a rapid onset of therapeutic effects (local or systemic). Nasal applications of topical decongestants or anti-inflammatory drugs are most popular topical nasal drug deliveries. Nasal delivery is the logical choice for treatment of diseases in the nose and paranasal sinuses. Over the years, nasal route has gained widespread interest as a promising and an alternative route to oral and parenteral drug delivery.
Growing prevalence of asthma and chronic obstructive pulmonary disease (COPD), increasing adoption of self-administration practices, and increasing preference for nasal drug delivery are some major factors expected to boost the growth of the global nasal drug delivery mode market over the forecast period. Asthma is a major noncommunicable disease (NCD) that affects both children and adults. For instance, according to the Asthma and Allergy Foundation of America (AAFA), more than 25 million people in the U.S. have asthma, about 1 in 13 people. Moreover, over 20 million adults aged 18 and older have asthma in the U.S., and asthma rates are highest in Black adults in the United States.
- This report provides in-depth analysis of the global nasal drug delivery mode market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2026 to 2033), considering 2025 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the nasal drug delivery mode market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Merck & Co., Inc., Astra Zeneca, GlaxoSmithKline Plc, Mystic Pharmaceuticals, PendoPharm Inc., Bausch Health, 3M, Cadila Pharmaceuticals, Optinose, Dr. Reddy Laboratories, Neurelis Inc., Aptar Group, Johnson & Johnson Services Inc., ENT Technologies Pty Ltd., and Becton, Dickinson and Company, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global nasal drug delivery mode market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nasal drug delivery mode market.
-
-
-
- Pressurized Container
- Non Pressurized
- Container
-
- Multi- Dose
- Bi-Dose
- Unit Dose
-
- Hospitals
- Homecare Settings
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
-
- Merck & Co., Inc.
- AstraZeneca
- GlaxoSmithKline plc (GSK)
- Mystic Pharmaceuticals
- Johnson & Johnson Services Inc.
- PendoPharm Inc.
- Bausch Health Companies Inc.
- 3M Company
- Cadila Pharmaceuticals Ltd.
- OptiNose Inc.
- Reddy’s Laboratories Ltd.
- ENT Technologies Pty Ltd.
- Neurelis Inc.
- AptarGroup, Inc.
- Becton, Dickinson and Company
